COPD

D9180C00002


FRONTIER4 COPD STUDY

Study Title

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of MEDI3506 in Participants with Moderate to Severe Chronic Obstructive Pulmonary Disease and Chronic Bronchitis (FRONTIER 4).

Study duration

Up to 41 weeks

Number of CLINIC VISITS

13 clinic visits

NUMBER OF PHONE CALLS

1 phone call

Main entry criteria
  • 40-75 years of age
  • Confirmed diagnosis of COPD for at least 1 year
  • Current or former cigarette smoker
  • Have had at least 1 COPD exacerbation requiring treatment with antibiotics or oral steroids, or had at least 1 hospitalisation for COPD in the past 24 months
  • Taking inhaled medication to treat your COPD

There are additional eligibility requirements to enrol in this study. Our Study Doctor will review the study requirements and discuss your eligibility with you either over the telephone or at your first clinic visit.

Assessments
  • Breathing tests
  • Blood pressure and pulse
  • Questionnaires
  • Cough count monitoring
  • Sputum sampling
  • Nasal sampling
  • ECGs
  • Blood tests

You will receive all study-related procedures, medications, and laboratory services at no cost. In addition, you will be reimbursed $50 per visit for your time and travel.

D3251C00014


RESOLUTE COPD Study

Study Title

A Multi-centre, Randomized, Double-Blind, Chronic-Dosing, Parallel-Group, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 g in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE).

Study duration

Up to 3 years

Number of CLINIC VISITS

Up to 23 clinic visits

Number of phone calls

Up to 19 phone calls

Main entry criteria
  • 40-85 years of age
  • Confirmed diagnosis of COPD
  • Current or former cigarette smoker
  • Have had at least 2 COPD exacerbations requiring treatment with oral steroids or requiring hospitalisation in the past 12 months
  • Taking inhaled medication to treat your COPD

There are additional eligibility requirements to enrol in this study. Our Study Doctor will review the study requirements and discuss your eligibility with you either over the telephone or at your first clinic visit.

Assessments
  • Breathing tests
  • Blood pressure and pulse
  • Questionnaires
  • ECGs
  • Blood tests

You will receive all study-related procedures, medications, and laboratory services at no cost. In addition, you will be reimbursed $50 per visit for your time and travel.

GB43311


COPD Study

Study Title

A Phase IIB, randomised, double-blind, placebo-controlled, multi-centre study to evaluate the efficacy and safety of astegolimab in patients with chronic obstructive pulmonary disease.

Study duration

62 weeks

Number of CLINIC VISITS

29 clinic visits

Main entry criteria
  • 40 – 90 years of age
  • Confirmed diagnosis of COPD
  • Have had at least 2 COPD exacerbations requiring treatment with oral steroids or requiring hospitalisation over a continuous 12-month period within the past 24 months.
  • Current or former cigarette smoker
  • Taking medication(s) to treat your COPD

There are additional eligibility requirements to enrol in this study. Our Study Doctor will review the study requirements and discuss your eligibility with you either over the telephone or at your first clinic visit.

Assessments
  • Breathing tests
  • Blood pressure and pulse measurements
  • Electronic Diary Questionnaires
  • ECGs
  • Blood tests
  • Sputum sampling

You will receive all study-related procedures, medications, and laboratory services at no cost. In addition, you will be reimbursed $100 per visit for your time and travel.

Loading...